Surgery – Blood drawn and replaced or treated and returned to body – Constituent removed from blood and remainder returned to body
Reexamination Certificate
2011-01-18
2011-01-18
Deak, Leslie (Department: 3761)
Surgery
Blood drawn and replaced or treated and returned to body
Constituent removed from blood and remainder returned to body
C210S646000, C210S645000, C210S739000, C604S006090, C604S006110
Reexamination Certificate
active
07871390
ABSTRACT:
A continuous renal replacement therapy (CRRT) device is provided that weighs between 2 and 10 pounds. The CRRT device can be portable, mobile or completely worn on the person of the patient. Blood and dialysate are each pumped in a pulsed or pulsatile manner through a dialyzer such that a significant portion of the peak pulse of the blood flow coincides with a significant portion of a low pulse portion of the dialysate flow. An differential pressure between a dialysate inlet of the dialyzer and the blood inlet of the dialyzer periodically changes from a high differential pressure of between 70 and 120 mmHg for a first time period and a low differential pressure of between −10 and 10 mmHg for a second time period. The frequency of the high and low differential pressure cycle is between about 0.5 and 4 Hz.
REFERENCES:
patent: 4765907 (1988-08-01), Scott
patent: 4828543 (1989-05-01), Weiss et al.
patent: 5011607 (1991-04-01), Shinzato
patent: 5284559 (1994-02-01), Lim et al.
patent: 5577891 (1996-11-01), Loughnane et al.
patent: 6200485 (2001-03-01), Kitaevich et al.
patent: 7276042 (2007-10-01), Polaschegg et al.
patent: 2003/0236482 (2003-12-01), Gorsuch et al.
patent: 2005/0101901 (2005-05-01), Gura
patent: 2006/0241543 (2006-10-01), Gura
patent: 2009/0101577 (2009-04-01), Fulkerson et al.
patent: 2009/0120864 (2009-05-01), Fulkerson et al.
patent: 2009/0282980 (2009-11-01), Gura
Gura, V., et al., “CRRT for ESRD. The Wearable Artificial Kidney. A Feasible, Safe and Cost Effective Way to Provide Daily Dialysis.”J. Am. Soc. Nephrol., 15 (2004) Abstract SU-PO478.
Gura, V., et al, “Pulsatile Blood and Dialysate Counter Phase Flows, Increased Sorbent Capacity and a High Flux Membrane Explain the High Efficiency of the Wearable Artificial Kidney (WAK).”J Am. Soc. Nephrol., 16 (2005) Abstract F-FC005.
Gura, V., et al., “The Wearable Artificial Kidney (WAK) Removes beta 2Microglobulins (B2M).”J. Am. Soc. Nephrol., 17 (2006) Abstract SA-PO708.
Gura, V., et al, “The Wearable Artificial Kidney (WAK), First Ambulatory Hemodiafiltration Human Trial.”J. Am. Soc. Nephrol., 18 (2007) Abstract SA-PO500.
Gura, V., et al, “The Wearable Artificial Kidney (WAK) Effectively Removes β2Microglobulin (β2M) and Phosphate (Phos) in Humans.”J. Am. Soc. Nephrol., 18 (2007) Abstract SΛ-PO501.
Gura, V., et al, “Continuous Renal Replacement Therapy for End-Stage Renal Disease. The Wearable Artificial Kidney (WAK),”Cardiovascular Disorders in Hemodialysis, Contrib Nephrol. Basel, Karger, 149:325-333 (2005).
Masamiki Miwa and Toru Shinzato, “Push/Pull Hemodiafiltration: Technical Aspects and Clinical Effectiveness,”Artificial Organs, 23(12): 1123-1128 (1999).
Rambod, E., et al., “The Impact of Pulsatile Flow on the Effectiveness of the WAK.”J. Am. Soc. Nephrol., 17 (2006) Abstract SA-PO707.
Runge, T.M., et al, “Hemodialysis: Evidence of Enhanced Molecular Clearance and Ultrafiltration Volume By Using Pulsatile Flow,”The International Journal of Artificial Organs, 16(9):645-652 (1993).
Sorbent Dialysis Primer, COBE Renal Care, Inc., 4thEd., pp. 1-46, Sep. 1993.
Non-Published U.S. Appl. No. 12/479,513, filed Jun. 5, 2009.
Ronco, C. et al., “The haemodialysis system: basic mechanisms of water and solute transport in extracorporeal renal replacement therapies,” Nephrology Dialysis Transplantation, 1998, pp. 3-9, Nephrol Dial Transplant (1998) [Suppl 6].
Ronco, Claudio et al., “Evolution of synthetic membranes for blood purification: the case of the Polyflux family,” Nephrology Dialysis Transplantation, 2003, pp. vii10-vii20, Nephrol Dial Transplant (2003) 18 [Suppl 7].
Jaffrin, M. Y. et al., “Rationale of Filtration Enhancement in Membrane Plasmapheresis by Pulsatile Blood Flow,” Life Support Systems, 1987, pp. 267-271.
Leypoldt, John K. et al., “Optimization of high-flux, hollow-fiber artificial kidneys,” Replacement of Renal Function by Dialysis, 2004, pp. 95-113, 5th Edition, Kluwer Academic Publishers, Great Britain.
Ronco, Claudio et al., “Blood and Dialysate Flow Distributions in Hollow-Fiber Hemodialyzers Analyzed by Computerized Helical Scanning Technique,” Journal of the American Society of Nephrology, 2001, pp. S53-S61, J Am Soc Nephrol 13.
Mineshima, Michio, “New trends in HDF therapies: Validity of Internal Filtration Enhanced Hemodialysis (IFEHD),” From the Kidney Center, Tokyo Women's Medical University, Japan, pp. 1-5.
Dellanna, F. et al., “Internal filtration—advantage in haemodialysis?” Nephrol Dial Transplant, 1996, 11 Suppl 2, pp. 83-86, Abstract retrieved from the internet, PMID: 8804002 [PubMed—indexed for MEDLINE].
Sanchez, Cesar et al., Continuous Venovenous Renal Replacement Therapy Using a Conventional Infusion Pump, ASAIO Journal, 2001, pp. 321-324.
Runge, T. M. et al., “Hemodialysis: evidence of enhance molecular clearance and ultrafiltration volume by using pulsatile flow,” The International Journal of Artificial Organs, 1993, pp. 645-652, vol. 16, No. 9., Wichtig Editore, 1993.
Siaghy, E. M. et al., “Consequences of static and pulsatile pressure on transmembrane exchanges during in vitro microdialysis: implication for studies in cardiac physiology,” IFMBE, 1999, pp. 196-201 Med. Biol. Eng. Comput. 37.
Jaffrin, Michel Y. et al., “Simultaneous Convective and Diffusive Mass Transfers in a Hemodialyser,” Transactions of the ASME, Journal of Biomechanical Engineering , May 1990, pp. 212-219, vol. 112.
Clark, William R. et al., “Determinants of haemodialyser performance and the potential effect on clinical outcome,” Nephrology Dialysis Transplantation, 2001, pp. 56-60, Nephrol Dial Transplant 16 [Suppl 5].
Ronco, C. et al., “Continuous versus intermittent renal replacement therapy in the treatment of acute renal failure,” Nephrology Dialysis Transplantation, 1998, pp. 79-85, Nephrol Dial Transplant 13 [Suppl6].
Marshall, Mark R. et al., “Sustained low-efficiency daily diafiltration (SLEDD-f) for critically ill patients requiring renal replacement therapy: towards an adequate therapy,” Nephrology Dialysis Transplantation, 2004, pp. 877-884, Nephrol Dial Transplant 19.
Huang, Zhongping et al., “A New Method to Evaluate the Local Clearance at Different Annular Rings Inside Hemodialyzers,” ASAIO Journal, 2003, pp. 692-697.
Maeda, Kenji et al, “Push/Pull Hemodiafiltration: Technical Aspects and Clinical Effectiveness,” Nephron, 1995, Editorial Review, pp. 1-9.
Shinzato, Toru et al., “Newly Developed Economical and Efficient Push/Pull Hemodiafiltration,” Effective Hemodiafiltration: New Methods, Contrib Nephrol, 1994, pp. 79-86, vol. 108.
Bosch, T. et al., “Effect of Protein Adsorption on Diffusive and Convective Transport Through Polysulfone Membranes,” Contr. Nephrol, 1985, pp. 14-22, vol. 46.
Pascual, Manuel et al., “Is adsorption an important characteristic of dialysis membranes?” Perspectives in Clinical Nephrology, 1996, pp. 309-313, Kidney International, vol. 49.
Ronco, C., “Continuous renal replacement therapies in the treatment of acute renal failure in intensive care patients,” Nephrology Dialysis Transplantation, 1994, pp. 191-200, Nephrol Dial Trnasplant 9 [Suppl 4].
Tsuruta, Kazuma et al., “A Simple Method for Clinical Application of Push/Pull Hemodiafiltration,” Effective Hemodiafiltration: New Methods, 1994, pp. 71-78, Contrib Nephrol, vol. 108.
Miwa, Toshihiko et al, “Which Kt/V Is the Most Valid for Assessment of Both Long Mild and Short Intensive Hemodialyses?” Nephron, 2002, pp. 827-831.
Ho, D. W. Y. et al., “Selective Plasma filtration for treatment of fulminant hepatic failure induced by D-galactosamine in a pig model,” Gut, 2002, pp. 869-876.
Rozga, Jacek et al., “A Novel Plasma Filtration Therapy for He
Gura Victor
Rambod Edmond
Deak Leslie
Fresenius Medical Care Holdings, Inc.
Hamilton Brook Smith & Reynolds P.C.
LandOfFree
Enhanced clearance in an artificial kidney incorporating a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Enhanced clearance in an artificial kidney incorporating a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enhanced clearance in an artificial kidney incorporating a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2661088